UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

UBS analyst Kevin Caliendo has upgraded Medpace Holdings (NASDAQ: MEDP) from a 'Sell' rating to 'Neutral.' Additionally, the price target for the stock has been raised significantly from $405 to $673.